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of	which	were	 defined	 by	 collagen	mutations.	Many	 new	 EDS	 variants	 have	 been	
discovered	 involving	 mutations	 that	 do	 not	 necessarily	 implicate	 collagen	
biosynthesis	 but	 do	 involve	 extracellular	 matrix	 (ECM)	 proteins.	 One	 of	 these	
proteins,	Aortic	Carboxypeptidase-Like	Protein	 (ACLP),	 is	 a	 large	 secreted	protein	
encoded	 by	 the	 AEBP1	 (adipocyte	 enhancer	 binding	 protein	 1)	 gene.	 Previous	
research	has	shown	that	ACLP	plays	a	vital	role	in	binding	collagen	via	its	discoidin	
domain	 and	 therefore	 regulates	 connective	 tissue	 assembly.	 Thus	 far,	 individuals	
from	 7	 different	 families	 have	 been	 identified	 with	 different	 EDS-causing	 ACLP	
mutations.	 Some	 mutations	 are	 ACLP	 null	 whereas	 other	 mutations	 lead	 to	
expressed	 mutant	 ACLP.	 One	 of	 these	 mutations	 is	 characterized	 by	 a	 single-
nucleotide	 deletion	 that	 causes	 the	 insertion	 of	 40	 amino	 acids	 in	 the	 discoidin	
domain	of	ACLP.	It	is	therefore	denoted	“ACLP-Ins40”.	The	goal	of	this	research	was	
to	 characterize	 the	 ACLP-Ins40	 protein	 and	 investigate	 how	 mutations	 in	 ACLP	
	
	 vi 
disrupt	 ECM	 homeostasis	 and	 cause	 EDS.	We	 initially	 sought	 to	 determine	 if	 the	
ACLP-Ins40	mutation	would	 alter	 ACLP’s	 ability	 to	 bind	 collagen.	 To	 achieve	 this	
goal	we	generated	expression	vectors	of	full	length	human	ACLP	carrying	the	Ins40	
mutation.	 By	 western	 blot,	 it	 was	 determined	 that	 ACLP-Ins40	 was	 not	 secreted	
from	 fibroblasts	 and	 was	 retained	 intracellularly.	 We	 then	 hypothesized	 that	 the	
retention	 of	 ACLP-Ins40	 in	 the	 secretory	 pathway	would	 induce	 ER	 stress	 due	 to	
misfolding.	 3T3	 fibroblasts	 were	 co-transfected	 with	 the	 ACLP-Ins40	 expression	
vector	 and	 an	 XBP1u-EGFP	 sensor	 of	 ER	 stress.	 Immunofluorescence	 imaging	
revealed	that	in	comparison	to	WT,	fibroblasts	expressing	ACLP-Ins40	experienced	
ER	stress	with	significantly	increased	spliced	XBP1.	This	may	then	cause	cell	death,	
the	 improper	 secretion	 of	 other	 important	 ECM	 proteins,	 or	 defective	 collagen	
scaffolding,	all	which	could	contribute	to	symptoms	of	EDS.	These	studies	contribute	
to	our	current	understanding	of	how	mutations	in	the	AEBP1	gene	and	alterations	in	







































































































































































structural	 and	 signaling	 roles	 in	 all	 organ	 systems	 (Vanakker	 et	 al.,	 2015).	
Connective	tissue	is	believed	to	be	derived	from	the	mesoderm	during	development	
and	 is	 generally	 categorized	 as	 soft/loose	 connective	 tissue	 or	 hard	 connective	
tissue	 such	as	bone	and	cartilage	 (Vanakker	et	al.,	2015).	 Soft	 connective	 tissue	 is	
embedded	 between	 other	 tissues/organs	 and	 typically	 consists	 of	 three	 key	
components-	 fibers	 (collagen	 and	 elastin),	 ground	 substance	 (glycoproteins	 and	





and	present	with	 a	 variety	 of	 phenotypes	 for	which	only	 symptomatic	 treatments	
currently	 exist	 (Vanakker	 et	 al.,	 2015).	 Two	 of	 the	 most	 common	 congenital	
connective	 tissue	 disorders	 are	 Ehlers-Danlos	 Syndromes	 (EDS)	 and	 Marfan	
Syndrome	 (MFS).	MFS	 displays	 an	 autosomal	 dominant	 inheritance	 pattern	 (Salik	
and	Rawla,	2018)	and	is	classified	as	an	elastinopathy	due	to	mutations	in	fibrillin-1	
assemblies	 (Cook	 and	 Ramirez,	 2014).	 Fibrillin-1	 assemblies	 are	 composed	 of	
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overlapping	microfibrils	 and	 elastic	 fibers	 that	 are	 ubiquitous	 components	 of	 the	
ECM	 (Cook	 and	 Ramirez,	 2014).	 Despite	 overlap	 in	 symptoms	 and	 implicated	
pathways,	 EDS	 is	 classified	 differently	 as	 a	 collagenopathy	 representing	 the	 first	
human	 disorder	 affiliated	 with	 defects	 in	 collagen	 biosynthesis	 (Vanakker	 et	 al.,	




EDS	 comprises	 a	 spectrum	 of	 heritable	 connective	 tissue	 disorders	 with	 varying	
genetic	 origins	 and	 clinical	manifestations	 (Beighton	 et	 al.,	 1998).	 Several	 distinct	
EDS	 subtypes	 have	 been	 identified;	 in	many	 cases	 it	 is	 inherited	 in	 an	 autosomal	
dominant	 or	 recessive	 manner	 but	 some	 cases	 have	 been	 shown	 to	 result	 from	
mutations	 occurring	 early	 on	 in	 development	 (Malfait	 and	 De	 Paepe,	 2014).	 EDS	
effects	 approximately	 1	 in	 every	 5,000	 individuals	 with	 no	 apparent	 distribution	
based	 on	 race,	 ethnicity,	 or	 geographical	 location	 (Vanakker	 et	 al.,	 2015).	 An	
increase	in	the	diagnosis	of	EDS	over	the	past	many	years	is	likely	due	to	increased	




EDS	 subtypes	were	 first	defined	 in	 the	1988	Berlin	nosology	which	delineated	11	
subtypes	 (Beighton	 et	 al.,	 1998).	 In	 1997,	 the	 Villefranche	 nosology	 identified	 6	
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distinct	 groups	 independently	 associated	 with	 fibrillar	 collagens	 (Beighton	 et	 al.,	
1998).	 These	 initial	 groups	 were	 classified	 based	 on	 certain	 major	 and	 minor	
criteria	and	included	the	molecular	and	biochemical	basis	when	known	(Beighton	et	
al.,	1998).	Since	the	initial	classification	in	1998,	many	new	EDS	variants	have	been	
established	 involving	 mutations	 in	 a	 series	 of	 new	 genes	 that	 do	 not	 necessarily	
involve	collagen	biosynthesis	(Weerakkody	et	al.,	2016).	 In	2017,	a	new	system	of	
EDS	 classification	 was	 established	 that	 outlined	 13	 subtypes,	 largely	 based	 on	
clinical	 criteria/hallmarks	 but	 also	 taking	 next-generation	 sequencing	 and	
molecular	diagnostic	strategies	into	account	(Malfait	et	al.,	2017).	In	this	way,	there	




in	COL5A1	 and	COL5A2	 genes	 (Ritelli	 et	 al.,	 2013).	Hypermobile	EDS	 shares	many	
features	 with	 Classic	 EDS	 but	 tends	 to	 involve	 more	 musculoskeletal	 symptoms	
although	 the	 genetic	 basis	 is	 still	 unknown	 (Malfait	 et	 al.,	 2017).	 Vascular	 EDS	 is	
caused	 by	 mutations	 in	 COL3A1,	 implicating	 type	 III	 collagen,	 and	 has	 the	 worst	
prognosis	due	to	risk	of	arterial	and	organ	rupture	(Pepin	et	al.,	2000).	In	this	case,	
























































The	 symptoms	 of	 EDS	 exhibit	 varying	 degrees	 of	 severity	 based	 on	 subtype	 and	
extent	 of	 disease	progression	 (Beighton	 et	 al.,	 1998).	A	defining	 clinical	 feature	 is	
soft	 tissue	 fragility	 that	 affects	 almost	 every	major	 organ	 system	 (Malfait	 and	 De	
Paepe,	 2014).	 EDS	 patients	 often	 display	 skin	 hyperextensibilty	 and	 are	 prone	 to	
lacerations	 and	 bleeding	 even	 following	 minor	 abrasions	 (Kosho	 et	 al.,	 2010).	
Wound	repair	 in	some	cases	 leads	 to	atrophic	scarring,	better	known	as	 ‘cigarette	
paper	 scars’,	 and	 in	 other	 cases	 results	 in	 more	 raised	 hypertrophic	 scarring	
(Parapia	and	Jackson).	Other	manifestations	include	easy	bruising,	vaginal	tears	and	
surgical	 complications	 such	 as	 wound	 dehiscence	 and	 hernias	 (Rombaut	 et	 al.,	
2011).			
	
Musculoskeletal	 symptoms	of	EDS	 include	 joint	hyperflexibility	 and	hypermobility	
which	 is	 assessed	 using	 the	Beighton	 Scale	 (Beighton	 et	 al.,	 1998).	 There	 are	 five	
tested	points	of	flexion	and	extension	for	which	unilateral	presence	receives	a	score	
of	one	and	bilateral	presence	receives	a	score	of	two	(Malfait	&	De	Paepe,	2014).	A	
















In	 some	 cases,	 symptoms	 associated	 with	 child	 abuse	 have	 been	 mistaken	 for	
symptoms	of	EDS	or	vice	versa.	As	early	as	1984,	a	case	was	reported	involving	a	6-
year-old	 girl	 who	was	 the	 subject	 of	 a	 child	 abuse	 evaluation	 but	 was	 then	 later	
diagnosed	 with	 EDS	 after	 thorough	 evaluation	 (Owen	 and	 Durst,	 1984).	 It	 is	
important	 to	 note	 that	 while	 some	 symptoms	 such	 as	 bruising	 and	 pronounced	
scarring	may	be	 indicative	of	EDS,	other	 symptoms	 such	a	 frequent	broken	bones	
and	 remodeling	 are	 not	 associated	with	 EDS	 (Castori,	 2015).	 It	 is	 crucial	 then	 to	
diagnose	 EDS	 based	 on	 the	 outlined	 criteria	 during	 a	 thorough	 in-person	 clinical	









the	 Beighton	 Scale	 (Malfait	 and	De	 Paepe,	 2014).	 In	 order	 to	 identify	 the	 specific	
subtype	of	EDS,	further	testing	is	needed.	Ultrastructural	examination	of	the	skin	by	
electron	 microscopy	 and	 fibroblast	 cultures	 from	 a	 skin	 biopsy	 can	 reveal	 more	
about	 the	 specific	 collagenous	 abnormalities	 (Malfait	 and	 De	 Paepe,	 2014).	
Biochemical	analysis,	urine	analysis,	molecular	analysis	and	preimplantation	genetic	
diagnosis	are	also	commonly	used	in	diagnosing	EDS	(Malfait	and	De	Paepe,	2014).	
Perhaps	 the	 largest	 diagnostic	 change	 has	 been	 the	 establishment	 of	 concrete	
criteria	 for	 Hypermobile	 EDS.	 This	 subtype	 was	 previously	 difficult	 to	 diagnose	
because	 of	 the	 overlap	 of	 many	 key	 symptoms	 with	 Classic	 EDS,	 and	 typically	
includes	 patients	 with	 more	 subtle	 symptoms	 (Camerota	 et	 al.,	 2014).	 Now,	 in	





is	 unique	 in	 their	 clinical	 presentation	 and	 circumstance	 (Malfait	 and	 De	 Paepe,	
2014).	 For	 example,	 athletes/active	 individuals,	 or	 individuals	 who	 may	 be	
undergoing	 surgery	 such	 as	 caesarean	 delivery,	 are	 at	 greater	 risk	 than	 others.	
Management	generally	requires	a	multi-disciplinary	approach	overseen	by	a	clinical	




ups,	 physiotherapy,	 pain	 management	 and	 psychological	 evaluations	 are	
recommended	 (Camerota	 et	 al.,	 2014).	 Vascular	 EDS	 involves	 more	 rigorous	
management	including	certain	prophylactic	measures	to	decrease	risk	of	pulmonary	
and	cardiac	complications	(Boone	et	al.,	2019).	Certain	activities	and	pregnancy	are	





discoveries	 point	 to	 defects	 proteins	 of	 the	 extracellular	 matrix	 (ECM)	 and	
glycosaminoglycan	 biosynthesis	 as	 contributors	 of	 this	 disease	 (Parapia	 and	
Jackson).	Collagen	 types	 I,	 III	 and	V	are	definitively	 linked	 to	many	EDS	 subtypes;	
this	 involves	 mutations	 leading	 to	 irregularities	 in	 collagen	 primary	 structure,	
collagen	processing,	collagen	folding	and	collagen	cross-linking	(Malfait	et	al.,	2017).	
In	 2001,	 it	was	 discovered	 that	 deficiencies	 in	 the	 ECM	protein	 tenascin-X	 (TNX),	
encoded	by	the	TNXB	gene,	caused	a	recessively	inherited	form	of	EDS	that	we	now	
know	 to	 be	 Classical-like	 EDS	 (Schalkwijk	 et	 al.,	 2009).	 In	 this	 case,	 TNX	 is	 not	
secreted	 by	 skin	 fibroblasts	 and	 is	 therefore	 absent	 in	 ECM	 (Zweers	 et	 al.,	 2003).	
Other	 studies	 have	 highlighted	 mutations	 the	 FKBP14	 gene	 (encoding	 proteins	
involved	 in	 pro-collagen	 binding),	 the	 PLOD1	 gene	 (encoding	 enzymes	 upstream	
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from	 collagen	 cross-linking),	 B4GALT7	 (encoding	 a	 galactotransferase	 crucial	 for	




The	 ECM	 itself	 is	 a	 non-cellular	 component	 present	 among	 all	 organs	 and	 tissues	
(Frantz	 et	 al.,	 2010).	 Comprised	primarily	 of	water,	 proteins	 and	polysaccharides,	
the	 ECM	 is	 also	 incredibly	 dynamic	 and	unique	 to	 the	 specific	 tissue	 it	 surrounds	
(Mouw	et	al.,	2014).	The	main	fibrous	proteins	include	collagens,	elastin,	fibronectin	
and	 laminins,	 of	which	 collagens	 are	 the	most	 abundant	 (Frantz	 et	 al.,	 2010).	The	
majority	 of	 fibrillar	 collagen	 is	 secreted	 from	 fibroblasts	 that	 help	 to	 organize	
collagen	 into	 a	 specific	 architecture	 of	 sheets	 and	 cables,	 creating	 a	 scaffold	 for	
further	 structural	 and	 signaling	 elements	 (Frantz	 et	 al.,	 2010).	 The	 relationship	
between	 cells	 and	 ECM	 is	 reciprocal-	 cells	maintain,	 repair	 and	 remodel	 the	 ECM	
through	 health	 and	 disease,	 while	 the	 ECM	 influences	 cell	 growth,	migration	 and	








The	 endoplasmic	 reticulum	 (ER)	 is	 the	 site	 of	 protein	 folding	 and	 multiple	
checkpoints	 for	 the	export	of	properly	 folded	proteins.	 It	 is	 therefore	a	 significant	
area	 of	 interest	 for	 those	hoping	 to	 explain	 the	molecular	 basis	 of	 certain	disease	




(PERK),	 activating	 transcription	 factor-6	 (ATF6),	 and	 inositol-requiring	 enzyme-1	














a	 frame	shift	and	creates	a	basic	 leucine	zipper	 (b-ZIP)	 transcription	 factor	 that	 is	









Various	 pathologies	 such	 as	 diabetes	mellitus,	 viral	 infections,	 neurodegeneration	
and	cancer,	have	been	linked	to	ER	stress	(Lin	et	al.,	2008).	This	can	be	traced	back	
to	defects	 in	 protein	 folding	mechanisms	or	 issues	 in	 the	 cell’s	 ability	 to	properly	
respond	 to	 the	 buildup	 of	 misfolded	 proteins	 which	 activates	 the	 UPR	 and	 can	
ultimately	 lead	 to	 cell	 death	 (Lin	 et	 al.,	 2008).	 With	 regard	 to	 connective	 tissue	
disease,	 it	 has	 been	 shown	 that	 collagen	 mutations	 (specifically	 associated	 with	
EDS)	result	in	increased	intracellular	retention	of	collagen,	increased	expression	of	
BiP	 and	 an	 up-regulation	 of	 other	 proteins	 carrying	 the	 ER-retention	 sequence	




protein	 synthesis	 and	 in	 extreme	 cases,	 apoptosis	 (Boot-Handford	 and	 Briggs,	
2009).	In	the	ECM,	this	can	cause	decreased	levels	not	only	of	collagen	or	the	protein	






measurements	 can	 be	 made	 using	 an	 ER-targeted	 redox-sensitive	 GFP	 that	 is	
designed	 to	 change	 fluorescence	 upon	 exposure	 to	 oxidizing	 environments	
(Oslowski	and	Urano,	2011).	UPR	activation	can	be	measured	by	analyzing	levels	of	
IRE1	 and	 PERK	 phosphorylation,	 or	 ATF6	 cleavage	 (Oslowski	 and	 Urano,	 2011).	







One	of	 the	proteins	 of	 the	ECM,	Aortic	 Carboxypeptidase-Like	Protein	 (ACLP)	 is	 a	





inactive	 carboxypeptidases	 (Layne	 et	 al.,	 1998).	 The	 protein	 is	 encoded	 by	 the	
AEBP1	(adipocyte	enhancer	binding	protein	1)	gene	on	chromosome	7	and	consists	
of	 an	 N	 terminal	 signal	 peptide	 involved	 in	 secretory	 pathways,	 a	
lysine/proline/glutamic	 motif	 that	 binds	 TGFβ	 (transforming	 growth	 factor	 β)	
(Kathleen	 Tumelty	 and	Matthew	 Layne,	 unpublished),	 a	 central	 discoidin	 domain	
that	binds	collagen,	and	a	C	terminal	domain	with	similarities	to	catalytically	active	
metallocarboxypeptidases	 (Blackburn	 et	 al.,	 2018;	 Reznik	 and	 Fricker,	 2001;	
Tumelty	and	Layne,	2013).	The	inactivity	of	the	ACLP	carboxypeptidase	domain	may	
be	 explained	 by	 its	 lack	 of	 the	 Glu270	 residue,	 deemed	 necessary	 for	 catalytic	
activity	 in	 related	proteins	 (Reznik	 and	Fricker,	 2001;	 Tumelty	 and	Layne,	 2013).	
Instead,	ACLP	 includes	Tyr847	 in	this	critical	position,	which	 is	unable	to	stabilize	
the	 active	 site	 conformation	 resulting	 in	 an	 inactivity	 of	 the	 carboxypeptidase	
domain	 (Tumelty	 and	 Layne,	 2013).	 This	 suggests	 that	 the	 ACLP	




ACLP	 is	 expressed	 early	 in	 the	 development	 of	 cells	 of	 the	 vasculature,	 dermis,	
connective	 tissue,	 and	 skeletal	 structures-	 an	 expression	 pattern	 consistent	 with	
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ACLP’s	 proposed	 function	 as	 a	 regulatory	 or	 structural	 protein	 amongst	 collagen	
rich	 tissues	 (Ith	 et	 al.,	 2005;	 Layne	 et	 al.,	 2001).	 In	 adult	 organisms,	 ACLP	 is	
primarily	 expressed	 in	 the	 vasculature,	 lung	 and	 skin	 (Tumelty	 and	Layne,	 2013).	
Given	its	broad	areas	of	expression	in	connective	tissue	cells,	it	is	hypothesized	that	
ACLP	 plays	 a	 homeostatic	 role	 in	 cell	 proliferation;	 in	 that	 the	 presence	 ACLP	
promotes	 cell	proliferation,	while	 the	 cells	 that	 lack	ACLP	proliferate	more	 slowly	
(Layne	et	al.,	2001).		
	
For	 example,	 there	 is	 increased	 ACLP	 accumulation	 in	 areas	 of	 adipose	 tissue	
fibrosis.	 Chronic	 high	 fat	 diets	 caused	 an	 increase	 in	 the	 secretion	 of	 ACLP	 from	
stromal	 progenitor	 cells	 (Jager	 et	 al.,	 2018).	 This	 in	 turn	 causes	 a	 shift	 towards	




High	 fat	 diets	 also	 increase	 ACLP	 expression	 in	 hepatic	 stellate	 cells	 (HSCs)	
(Teratani	et	al.,	2018).	Studies	on	nonalcoholic	steatohepatitis	(NASH)	discuss	ACLP	
as	 a	 ligand	 that	 activates	 the	 Wnt	 pathway	 and	 therefore	 exacerbates	 NASH	
pathology	(Teratani	et	al.,	2018).	The	proposed	mechanism	is	as	follows:	as	obesity-
related	 factors	 in	 serum	 increase,	 STAT3	 (signal	 transducer	 and	 activator	 of	
transcription	3)	signaling	 is	 increased	and	promotes	expression	of	ACLP	(Teratani	
et	 al.,	 2018).	 ACLP	 then	 activates	 Wnt	 signaling	 by	 binding	 frizzled-8	 and	 low-
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density	 lipoprotein–related	 receptor	6	 (Teratani	 et	 al.,	 2018).	As	ACLP	expression	




studied	 is	ACLP’s	 activation	of	TGFβ	 signaling	 in	 relation	 to	 Idiopathic	Pulmonary	
Fibrosis	 (IPF).	 IPF	 is	 characterized	 by	 increased	 activation	 of	 TGFβ	 and	 ECM	
remodeling	which	 causes	 collagen	accumulation	 and	 the	differentiation	of	 smooth	
muscle	α-actin	(SMA)-positive	myofibroblasts	(Tumelty	et	al.,	2014).	The	absence	of	
ACLP	in	mice	protects	against	lung	fibrosis,	lessening	the	amount	of	myofibroblasts	
and	 secreted	 collagen	 (Schissel	 et	 al.,	 2009).	 These	 studies	 support	 a	 model	 that	
ACLP	 regulates	 critical	 pathways	 related	 to	 cellular	differentiation	 and	 connective	





collagen	 fibrils	 via	 the	 aforementioned	 discoidin	 domain	 (Schissel	 et	 al.,	 2009).	 It	
has	been	further	shown	that	identified	mutations	in	the	AEBP1	gene	result	improper	
collagen	 assembly	 and	 connective	 tissue	 structure	 leading	 to	 symptoms	 of	 EDS	








Figure	1.	ACLP	mutations	 in	 EDS	patients.	Skin	hyperextensibility	(A)	and	 joint	
hypermobility	 (B)	 in	 ACLP/AEBP1	 compound	 heterozygous	 frameshift	 and	




Thus	 far,	 individuals	 from	 7	 different	 families	 have	 been	 identified	 with	 various	
EDS-causing	ACLP	mutations	 (Figure	 2,	 Table	 2).	Family	A	 includes	parents	each	
with	 a	 unique	 AEBP1	 mutation	 and	 their	 child	 who	 is	 therefore	 a	 compound	
heterozygote	and	presents	with	irregular	disrupted	collagen	fibrils	(Blackburn	et	al.,	
2018).	Family	B	is	made	up	of	a	single	patient	expressing	a	homozygous	frameshift	
deletion	 and	 whose	 skin	 examination	 revealed	 decreased	 dermal	 collagen	 when	
compared	 to	 heterozygous	 carriers	 (Blackburn	 et	 al.,	 2018).	 Family	 C	 has	 two	
siblings,	each	with	the	same	homozygous	truncating	variant	that	results	in	a	protein	
null	 and	 symptoms	 including	 disruptions	 in	 facial	 features	 and	 severe	 osteopenia	
(Alazami	et	al.,	2016).	Family	D	is	also	comprised	of	two	siblings	with	a	homozygous	
nonsense	truncating	mutation	but	this	time	in	exon	6,	upstream	from	the	discoidin	













terminal	 signal	 peptide,	 a	 TGFβ	 binding	 domain,	 a	 central	 discoidin	 domain	 that	
binds	collagen,	and	a	C	terminal	catalytically	inactive	carboxypeptidase-like	domain.	








Family	 Transcript	 Protein	 Reference	
A	 c.1470delC		 p.Asn490_Met495delins(40)	 Blackburn	2018	
		 c.1743C>A			 p.Cys581*	 		
B	 c.1320_1326del	(homo)	 p.Arg440Serfs*3	 Blackburn	2018	
C	 c.1630+1	G>A	(homo)			 unknown/null	 Alazami	2016,		Blackburn	2018	
D	 c.917dupA	(homo)	 p.Tyr306Terfs	 Hebebrand	2019	
E	 c.362dupA	(homo)	 p.Glu122Glyfs*16	 Syx	and	Malfait	2019	
F	 c.443dupA	 p.Ala149Glyfs*57	 Syx	and	Malfait	2019	
		 c.1149_1150+2delCAGT	 inframe	delete	38	aa	 		
G	 c.1925T>C	(homo)	 p.Leu642Pro	 Ritelli	2019	
	






the	 reading	 frame	 that	 caused	 a	 loss	 of	 the	 last	 6	 amino	 acids	 in	 exon	 12	 and	 an	
inclusion	 of	 40	 (previously	 absent)	 amino	 acids	 before	 returning	 to	 the	 in-frame	
translation	of	exon	13	(Blackburn	et	al.,	2018).	This	mutation	occurs	in	the	discoidin	
domain	of	ACLP,	which	in	its	undisturbed	state	would	preferentially	bind	collagens	






is	 to	 better	 understand	 ACLP-Ins40’s	 phenotype	 and	 how	 it	 disrupts	 ECM	
homeostasis	 in	a	way	that	results	 in	symptoms	of	EDS.	Our	initial	objective	was	to	
determine	if	the	mutation	(insertion	of	40	amino	acids)	would	alter	ACLP’s	ability	to	











patient	 fibroblasts	 as	 previously	 categorized	 (Blackburn	 et	 al.,	 2018).	 Fibroblast	
cDNA	was	generated	from	the	mRNA	using	the	Maxima	First	Strand	cDNA	Synthesis	
Kit	 for	 RT-qPCR	 (Thermo	 Scientific,	 K164)	 and	 then	 amplified	 using	 a	 forward	







































were	 cloned	 into	 the	 pCMV6-hACLP-WT-myc-DDYK	 (Origene,	 RC207782)	 and	
pCMV6-hACLP-WT	 (Origene	 SC309967)	 plasmids.	 Both	 the	 PCR	 products	 and	





Fragments	were	 ligated	 using	 Quick	 Ligation	 Kit	 (New	 England	 Biolabs	M2200S).	





Catabolite	 repression	 (SOC)	 was	 added	 (500	 µL/transformation),	 followed	 by	
incubation	 on	 a	 rotating	 wheel	 at	 37°C	 for	 one	 hour.	 Bacteria	 were	 plated	 on	




Bacterial	 colonies	were	 selected	 and	 inoculated	 into	 3	ml	 of	 Lysogeny	 broth	 (LB)	
with	 either	 100	 µg/ml	 ampicillin	 or	 50	 µg/ml	 kanamycin	 and	 grown	 overnight.	
Plasmid	 DNA	 was	 prepared	 using	 QIAprep	 Spin	 Miniprep	 Kit	 (Qiagen	 27104).	
Plasmids	 	were	 verified	 by	 EcoRI	 and	BamHI	 restriction	 digests	 followed	 by	DNA	






AD-293	 cells	 (Stratagene)	were	 routinely	 cultured	 in	DMEM	 (Dulbecco’s	Modified	
Eagle’s	medium)	 supplemented	with	 10%	 fetal	 bovine	 serum	 (FBS,	Hyclone),	 100	
µg/ml	 penicillin,	 100	 µg/ml	 streptomycin,	 and	 2	mM	 L-glutamine	 (PSG,	 Corning).	









Ins40)	and	3	µl	of	TransIT-2020	 (Mirus	Bio)	 reagent	 in	Opti-MEM	reduced	 serum	
media	 supplemented	 with	 Gluta-MAX	 (Invitrogen)	 for	 24	 hours.	 Transfection	
efficiency	was	monitored	by	transfection	of	pMax-GFP	(Lonza)	in	separate	wells	and	
was	 routinely	 between	 30-50%.	 3T3	 fibroblasts	 were	 transfected	 using	 the	 same	









3T3	 fibroblasts	 were	 seeded	 in	 12	 well	 plates	 at	 100,000	 cells	 per	 well	 and	
cotransfected	with	 0.75	 µg	 plasmid	DNA	 (ACLP-WT-FLAG	 or	ACLP-Ins40-FLAG)	 +	
0.25	 µg	 pcDNA	 3.1	 plasmid	 expressing	 the	 Neomycin	 gene.	 Cells	 were	 then	
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transferred	 to	 p100	petri	 dishes	 and	 subsequently	 selected	with	1mg/ml	G418	 in	
DMEM	with	FBS+PSG.	Colonies	were	pooled,	expanded	and	expression	of	ACLP	was	
determined	 by	 immunofluorescence	 staining	with	 Cy3-tagged	 anti-FLAG	 antibody	
















Protein	 concentrations	 determined	 using	 Pierce	 BCA	 Protein	 Assay	 Kit	






to	 an	 equivalent	 volume.	 Conditioned,	 concentrated	 media	 was	 aliquoted	 to	 the	
same	 volume.	 5x-loading	 buffer	 (0.25%	 bromophenol	 blue,	 0.5	 M	 DTT,	 50%	
glycerol,	10%	SDS,	0.25	M	Tris)	was	added	to	each	sample.	The	samples	were	heated	
at	99°C	for	4	minutes	and	run	on	6%	Tris-Glycine	gels	(Thermo-Fischer)	at	193	volts	
for	 80	 minutes.	 The	 gel	 was	 transferred	 onto	 a	 nitrocellulose	 membrane	 (GE	
Healthcare)	 using	 transfer	 buffer	 containing	 48	 mM	 Tris	 pH	 8.3,	 39	 mM	 glycine,	
0.037%	 SDS,	 and	 20%	methanol.	 The	 transfer	 ran	 overnight	 at	 23	 volts	 in	 a	 4°C	
room.	The	 following	morning,	 the	membrane	washed	 in	TBST	buffer	 (25	mM	Tris	
pH	 8.0,	 125	 mM	 sodium	 chloride,	 and	 0.1%	 Tween	 20)	 for	 a	 few	 minutes.	 The	
membrane	 was	 then	 blocked	 in	 4%	 milk	 in	 TBST	 for	 40	 minutes	 at	 room	
temperature.	Primary	antibody,	rabbit	anti	mouse-ACLP,	was	diluted	1:4000	in	4%	




TBST.	 Membranes	 were	 placed	 in	 between	 pieces	 of	 transparency	 film	 and	














for	1	hour.	 Slides	were	 then	washed	 twice	 in	PBST	and	 twice	again	 in	PBS.	 Slides	





Slides	 were	 imaged	 using	 Zeiss	 fluorescent	 microscope	 and	 Zenpro	 software.	
Exposure	times	were	optimized	based	on	the	sample	set	and	kept	constant	for	each	
sample	 within	 a	 single	 experiment.	 Images	 were	 analyzed	 with	 Fiji	 software.	












EDS	 is	 a	 disease	 that	 impacts	 connective	 tissue	 by	 disrupting	 the	 homeostasis	 or	
collagen	 and/or	 other	 proteins	 of	 the	 ECM.	 The	 goal	 of	 this	 project	 was	 to	
characterize	how	specific	AEBP1	mutations	cause	EDS	and	to	examine	the	collagen	
binding	 properties	 of	 a	 specific	ACLP	 intron	 retention	mutation	 (Figure	 3).	 ACLP	
has	been	identified	as	a	key	protein	in	the	ECM,	necessary	for	binding	collagen	and	
helping	to	create	its	unique	architecture	(Layne	et	al.,	2001).	Previous	experiments	
in	 our	 laboratory	 had	 shown	 that	 a	 recombinant	 form	 of	 this	 mutated	 discoidin	
domain	 of	 ACLP	 did	 not	 exhibit	 specific	 binding	 to	 collagen	 and	 in	 fact	 exhibited	





























full-length	 wildtype	 human	 ACLP	 that	 was	 then	 exchanged	 with	 the	 N-terminal	
mutated	 fragment	 (cloning	scheme	depicted	 in	Figure	 4).	Plasmids	harboring	 this	






























terminal	 region	 of	 the	 human	 ACLP	 cDNA	 harboring	 the	 Ins40	 mutation	 was	






















	 	 	 	 	 		
pCMV6-ACLP-
Ins40 
































in	AD293	 cells.	 These	 cells	were	 chosen	because	 they	do	not	 express	 endogenous	
ACLP	and	 for	 the	 ease	of	 transfection.	AD293	 cells	were	 transfected	with	pCMV6-
ACLP-WT	 or	 pCMV6-ACLP-Ins40	 plasmids	 and	 after	 24	 hours,	 total	 cell	 protein	
lysates	 and	 conditioned	media	were	 collected.	 Protein	 concentrations	 of	 the	 total	




(Figure	 6).	Both	ACLP-WT	and	ACLP-Ins40	were	 readily	detected	 in	 the	 total	 cell	
lysates.	Consistent	with	 the	endogenous	ACLP-Ins40	protein	(Blackburn	et	al),	 the	
transfected	 ACLP-Ins40	 protein	 exhibited	 a	 slower	mobility	 on	 the	 gel	 consistent	
with	a	 larger	molecular	weight.	ACLP-WT	was	 readily	detected	 in	 the	 conditioned	
media	 and	 the	 larger	 size	was	 likely	due	 to	N-linked	glycosylation	 in	 the	 secreted	
protein	 (Teratani	 et	 al.,	 2018).	 In	 contrast,	 ACLP-Ins40	 was	 not	 detected	 in	 the	
conditioned	media	indicating	that	it	was	not	secreted	from	these	cells.	These	results	


















Figure	 6.	 ACLP-Ins40	 is	 not	 secreted	 from	 AD293	 cells.	 293	 cells	 were	
transiently	transfected	with	pCMV6-ACLP	or	pCMV6-ACLP-Ins40	plasmids	and	total	
protein	 and	 conditioned	 media	 was	 collected	 after	 24	 hours.	 Western	 blot	 was	
performed	 on	 25	 µg	 of	 total	 protein	 and	 equal	 volumes	 of	 50-fold	 concentrated	
conditioned	media	with	 antibodies	 against	 ACLP.	 Both	 ACLP-WT	 and	 ACLP-Ins40	
proteins	were	detected	in	cell	lysates	and	only	the	ACLP	protein	was	detected	in	the	

























that	 it	 was	 being	 retained	 intracellularly.	 To	 test	 this,	 3T3	 fibroblasts	 were	
transiently	 transfected	with	WT	and	Ins40	expression	plasmids	containing	a	FLAG	
epitope	tag.	Fibroblasts	were	chosen	for	these	studies	due	to	their	role	in	connective	




Immunofluorescence	 microscopy	 revealed	 that	 both	 ACLP-WT	 and	 ACLP-Ins40	
exhibited	 a	 perinuclear	 expression	 pattern	 (Figure	 7)	 that	 is	 consistent	 with	
translocation	 into	 the	 ER.	 In	 some	 cells	 transfected	 with	 ACLP-Ins40,	 a	 gap	 in	


























Figure	 7.	 Perinuclear	 expression	 pattern	 of	 both	 ACLP	 and	 ACLP-Ins40	
proteins	 in	 fibroblasts.	 3T3	mouse	 fibroblasts	were	 transiently	 transfected	with	
pCMV6-ACLP-WT-Flag	or	pCMV6-ACLP-Ins40-Flag	plasmids	and	fixed	with	4%	PFA	
after	24	hours.	Cells	were	stained	with	a	Cy3-conjugated	anti-FLAG	antibody	prior	









































Figure	 8.	 Absence	 of	 ACLP-Ins40	 protein	 expression	 in	 the	 Golgi.	 3T3	
fibroblasts	 transfected	 and	 imaged	 as	 in	 Figure	 6,	 were	 imaged	 at	 100x	





























Mutations	 in	 other	 ECM	 proteins	 that	 cause	 connective	 tissue	 disease	 including	
collagen	 VI	 and	 collagen	 III	 induce	 ER	 stress	when	 retained	 intracellularly	 (Boot-
Handford	 and	 Briggs,	 2009).	 Therefore,	 experiments	 were	 performed	 to	 test	 the	

































Figure	 9.	 Validation	 of	 XBP1s	-EGFP	 ER	 stress	 sensor.	 3T3	 fibroblasts	 were	
transiently	 transfected	 with	 the	 XBP1u-EGFP	 plasmid	 and	 after	 12	 hours	 were	
treated	with	either	2	µg/ml	tunicamycin	or	1	µM	thapsigargin	 to	induce	ER	stress.	
After	 15	 hours	 cells	 were	 fixed,	 stained	 with	 DAPI	 and	 mounted	 and	 imaged.	
Compare	 with	 untreated	 controls,	 nuclear	 EGFP	 expression	 was	 detected	 in	 the	























































mouse	 fibroblasts	 were	 transiently	 co-transfected	 with	 pCMV6-ACLP-WT-Flag	 +	
XBP1u-EGFP	or	pCMV6-ACLP-Ins40-Flag	+	XBP1u-EGFP	plasmids	and	fixed	with	2%	
PFA	 after	 24	 hours.	 Cells	were	 stained	with	 a	 Cy3-conjugated	 anti-FLAG	 antibody	
prior	 to	 counterstaining	 the	 nuclei	 with	 DAPI	 and	 mounting,	 and	 imaging.	 Both	
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by	 the	 retention	 of	 an	 intron.	 These	 studies	 developed	 new	 tools	 to	 identify	 the	
mechanisms	 of	 EDS	 caused	 by	 mutations	 in	 the	 AEBP1	 gene.	 A	 plasmid	 was	
generated	that	harbored	this	mutation	and	contained	a	FLAG	epitope	tag.	Western	











novel	 variant	of	EDS.	To	achieve	 this	 goal	we	generated	expression	vectors	of	 full	
length	 human	 ACLP	 carrying	 the	 Ins40	 mutation	 (in	 both	 tagged	 and	 untagged	
plasmids).	 By	western	 blot,	 it	 was	 determined	 that	 ACLP-Ins40	was	 not	 secreted	
from	 fibroblasts	 and	was	 retained	 intracellularly.	We	 then	hypothesized	 that	 cells	
expressing	ACLP-Ins40	would	undergo	ER	stress.	To	test	this	hypothesis,	fibroblasts	
were	 co-transfected	 with	 an	 XBP1	 sensor	 of	 ER	 stress.	 Immunofluorescence	
experiments	 revealed	 that	 in	 comparison	 to	 WT,	 ACLP-Ins40	 expressing	 cells	
exhibited	significantly	more	ER	stress.	These	results	of	non-secretion	and	ER	stress	





ACLP-Ins40.	Previous	 findings	 from	our	 laboratory	 indicated	that	 the	recombinant	
discoidin	 domain	 harboring	 the	 Ins40	 mutation,	 generated	 in	 bacteria,	 exhibited	
what	appeared	to	be	non-specific	collagen	binding	(Rose	Zhao	and	Matthew	Layne,	




exchanged	 with	 the	 N-terminus	 of	 the	 ACLP-Ins40	 cDNA,	 which	 contains	 the	
mutated	 discoidin	 domain	 with	 contained	 the	 deleted	 cytosine	 and	 subsequent	
insertion	(Figure	4).	The	first	cloned	plasmid	(pCMV6-ACLP-Ins40,	untagged)	was	
used	 to	 transiently	 transfect	 AD-293	 cells	 and	 determine	 protein	 expression.	
Collection	 of	media	 and	 total	 protein	 lysates	 showed	 that	ACLP-Ins40	protein	 did	
not	appear	in	the	concentrated	media	sample	(Figure	6).	Long	exposure	times	and	
multiple	 independent	 experiments	 showed	 that	 ACLP-Ins40	 was	 entirely	 absent	
from	all	media	samples	and	indicates	that	it	was	therefore	not	secreted.	This	may	be	







secreted	 into	 the	 ECM.	 It	 is	worth	 noting	 that	while	 both	 forms	 are	 retained,	 the	
mechanisms	involved	may	be	entirely	different.		
	
To	 examine	 whether	 the	 ACLP-Ins40	 exhibited	 intracellular	 retention,	 3T3	
fibroblasts	were	transfected	with	an	expression	vector	of	ACLP-Ins40	attached	with	
a	FLAG	epitope	tag.	This	facilitated	staining	with	an	anti-FLAG	antibody	to	visualize	
ACLP	 localization.	 As	 with	 ACLP-WT,	 ACLP-Ins40	 exhibited	 a	 perinuclear	 pattern	
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suggesting	 the	 protein	was	 translated	 and	 reached	 the	 ER	 (Figure	 7).	 This	 result	
supports	the	notion	that	the	ACLP-Ins40	protein	translocates	into	the	ER	where	it	is	
possibly	 retained	 and	 therefore	 not	 secreted.	 Consistent	 with	 the	 human	 ACLP	
pattern,	 previous	 experiments	 done	 to	 evaluate	 ACLP	 expression	 in	mouse	 aortic	
smooth	muscle	cells	also	showed	a	predominantly	perinuclear	pattern	(Layne	et	al.,	
2001).	Increased	signal	strength	of	ACLP	in	cells	transfected	with	ACLP-Ins40-FLAG	
over	ACLP-WT-FLAG	may	point	 to	 accumulation	of	 the	mutated	protein	 in	 the	ER	
and	 further	studies	are	needed.	We	did	note	a	potential	absence	of	ACLP-Ins40	 in	
what	appears	to	be	the	Golgi	complex	(Figure	8),	which	provides	further	evidence	
that	 ACLP-Ins40	 does	 not	 undergo	 normal	 trafficking	 as	 part	 of	 the	 secretory	
pathway.		
	
ACLP	 is	 a	 necessary	 component	 of	 collagen’s	 architecture	 within	 the	 ECM	
(Blackburn	 et	 al.,	 2018;	Tumelty	 and	Layne,	 2013).	 Previous	 experiments	 showed	





and	 collagen	 are	 closely	 linked	 especially	 during	 settings	 of	 injury	 as	 observed	
during	bleomycin-induced	lung	damage	(Schissel	et	al.,	2009).	It	was	observed	that	
ACLP-deficient	 lung	 fibroblasts	 exhibit	 defects	 in	 cell	 spreading,	 proliferation,	 and	
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contraction	 on	 collagen	 matrices	 (Schissel	 et	 al.,	 2009).	 These	 studies	 also	
determined	 that	 ACLP’s	 discoidin	 domain	 is	 likely	 the	 key	 regulator	 in	 binding	
collagen.	 Solid	 phase	 binding	 assays	 have	 shown	 that	 purified	 recombinant	
discoidin	domain	binds	several	collagens	but	has	a	preference	for	collagen	types	I,	
III	 and	V-	 the	 very	 types	mutated	 in	 other	EDS	 subtypes	 (Blackburn	 et	 al.,	 2018).	
Other	experiments	examined	ACLP’s	role	in	collagen	polymerization	in	vitro–	here	it	
was	 observed	 that	 when	 full-length	 recombinant	 ACLP	 is	 added	 to	 denatured	








Given	what	 is	 known	about	 the	 intracellular	 retention	of	 collagen	 associated	with	
increased	 BiP	 and	 the	 UPR	 (Gould	 et	 al.,	 2007),	 it	 was	 hypothesized	 that	 the	
retention	 of	 ACLP-Ins40	 could	 activate	 ER	 stress	 pathways.	 The	 insertion	 of	 40	
amino	 acids	 could	 cause	misfolding	which	would	 recruit	BiP	 to	bind	 and	 stabilize	
the	 hydrophobic	 regions	 of	 the	 protein	 (Yoshida	 et	 al.,	 2001).	 As	 a	 result,	 BiP	
dissociates	from	the	intracellular	receptor	domains	(PERK,	IRE1,	ATF6),	which	leads	









Imaging	 studies	 suggested	 that	 in	 comparison	 to	 the	 control,	 the	 majority	 of	
fibroblasts	expressing	ACLP-Ins40	undergo	ER	stress.	In	these	cases,	it	seemed	to	be	
that	 cells	 with	 the	 strongest	 ACLP	 signal	 (the	 brightest	 perinuclear	 red)	 also	
exhibited	the	strongest	XBP1s-EGFP	signal	(the	brightest	nuclear	green)	(Figure	10,	
and	data	not	shown).	Signal	strength	between	the	two	indicators,	ACLP	and	XBP1s-
EGFP,	 appeared	 to	match	 each	 other	 providing	 further	 visual	 evidence	 that	 ACLP	
accumulation	 in	 the	ER	(due	to	the	 Ins40	mutation	 in	 this	case)	 is	associated	with	
increased	 levels	 of	 ER	 stress;	 however,	 additional	 studies	 are	 needed	 to	 establish	
this	 finding.	 It	 was	 also	 observed	 in	 experiments,	 generating	 stable	 cell	 lines	 of	













al.,	 2017).	There	 are	 currently	13	 subtypes	of	EDS,	 although	ACLP	mutations	may	
soon	constitute	a	14th	category	of	EDS,	sharing	multiple	clinical	features	with	other	
subtypes	 but	 with	 an	 entirely	 independent	 cause	 (Malfait	 et	 al.,	 2017).	 This	 new	
subtype	 would	 likely	 fit	 into	 Group	 B:	 Disorders	 of	 collagen	 folding	 and	 collagen	
cross-linking	 (Table	 1)	 given	 what	 is	 known	 about	 ACLP’s	 interactions	 with	
collagen	(Ith	et	al.,	2005;	Layne	et	al.,	2001).		
	
Individuals	 with	 AEBP1	 mutations	 display	 clinical	 characteristics	 similar	 to	
symptoms	of	Classical-like	EDS	and	Hypermobile	EDS:	Beighton	score	of	8	out	of	9,	





TNX.	 Although	 there	 are	 many	 similarities	 with	 the	 Classical-like	 subtype,	 EDS	
symptoms	 caused	 by	 ACLP	mutations	 can	 also	 fall	 under	 the	 other	 subtypes.	 For	
example,	patients	in	Family	A	(Table	2)	were	diagnosed	with	mitral	valve	prolapse	
and	 aortic	 root	 dilation-	 symptoms	 typically	 associated	 with	 Vascular	 EDS	
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(Blackburn	 et	 al.,	 2018).	 Patient	 one	 from	 Family	 E	 presented	 with	 pectus	
excavatum	and	suffered	a	 spontaneous	pneumothorax	 in	adulthood,	which	 is	only	
ever	seen	 in	Vascular	EDS	(Syx	et	al.,	2019).	The	patients	 from	Family	C	with	null	
ACLP	 protein	 expression,	 likely	 as	 a	 result	 from	 mRNA	 decay,	 exhibited	 severe	
osteopenia,	severe	joint	and	skin	laxity	as	well	as	disruptions	in	their	facial	features	
(Alazami	 et	 al.,	 2016).	 In	 this	 case,	 it	 appears	 that	 the	 complete	 absence	 of	 ACLP	
caused	the	most	common	clinical	 features	of	EDS	to	be	experienced	to	an	extreme	
degree.	 Patients	 from	 Family	 D	 were	 kyphoscoliotic	 as	 is	 usually	 seen	 in	
Kyphoscoliotic	 EDS	 (Hebebrand	 et	 al.,	 2019).	 The	mutation	 described	 in	 Family	 F	
encodes	 for	 a	 proline	 substitution	 whose	 ring	 structure	 is	 likely	 to	 cause	 a	
misfolding.	 The	 variant	 localization	 may	 play	 a	 role	 in	 the	 phenotypic	 variability	
seen,	but	may	also	not	be	directly	responsible	as	most	of	the	mutations	are	loss-of-












Our	 studies	 have	 shown	 that	 the	 Ins40	 mutation	 of	 ACLP	 results	 in	 intracellular	
retention	 of	 the	mutant	 protein	 and	 ER	 stress.	 From	 here	 there	 are	many	 future	
directions	that	can	be	taken	to	try	and	pinpoint	the	exact	role	that	ACLP-Ins40	plays	








help	 to	 characterize	 other	 ACLP	mutations	 of	 a	 similar	 nature.	 Research	 in	 these	
areas	may	provide	exciting	targets	for	pharmacologic	and	therapeutic	interventions	
in	treating	EDS.		
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